Arvinas Announces Changes to its Board of Directors
17 December 2022 - 1:00AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that Brad Margus, M.B.A., has stepped
down from the company’s Board and Everett Cunningham has been
appointed to join.
“We are very appreciative of Brad’s contributions to the
development and success of Arvinas, particularly in his role as a
member of our Audit Committee,” said John Houston, Ph.D., President
and Chief Executive Officer at Arvinas. “We will miss him and his
inspiring leadership, and we wish him the best of luck in his
future endeavors.”
Mr. Cunningham joins Arvinas’ Board with over 25 years of
experience in pharmaceuticals and medical services and a commitment
to leadership excellence. He currently serves as Chief Commercial
Officer at Exact Sciences and was previously President & CEO of
GE Healthcare’s U.S. & Canada regions. Prior to that, he served
as Senior Vice President, Commercial, at Quest Diagnostics where he
was responsible for global commercial sales, marketing, and
commercial operations. He also spent 21 years at Pfizer in numerous
senior leadership roles, including Regional President, Established
Products for Asia Pacific.
Additionally, Mr. Cunningham has served on the board of American
Family Children's Hospital in Madison, WI, since 2021 and Visby
Medical in San Jose, CA, since 2022. He earned his bachelor’s
degree in economics from Northwestern University.
“Everett is an outstanding strategic leader with extensive
experience in the pharmaceutical, medical services, and cancer
diagnostics industries, and I am excited to welcome him to Arvinas’
Board of Directors,” said Dr. Houston. “I am confident that his
leadership and expertise will be highly valuable to Arvinas,
especially as it relates to commercialization.”
“I share Arvinas’ passion to improve the lives of patients with
serious diseases,” added Mr. Cunningham. “I am excited to join the
team and contribute to Arvinas’ success, especially as the company
transitions to late-stage development.”
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC®
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs:
bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with
metastatic castration-resistant prostate cancer; and ARV-471 for
the treatment of patients with locally advanced or metastatic
ER+/HER2- breast cancer. For more information, visit
www.arvinas.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties, including statements regarding the potential
advantages and therapeutic benefits of our product candidates, the
future development and potential marketing approval and
commercialization of our product candidates, including the
initiation of and timing of data from our clinical trials. All
statements, other than statements of historical facts, contained in
this press release, including statements regarding our strategy,
future operations, prospects, plans and objectives of management,
are forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make as a result of various risks and uncertainties,
including but not limited to:, whether we will be able to
successfully conduct and complete clinical development of our
product candidates, including whether we initiate and receive
results from our clinical trials on our expected timelines or at
all, obtain marketing approval for and commercialize our product
candidates on our current timelines or at all and other important
factors discussed in the “Risk Factors” sections contained in our
quarterly and annual reports on file with the Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect our current views with respect to future
events, and we assume no obligation to update any forward-looking
statements except as required by applicable law. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this release.
Contacts
Investors:Jeff
Boyle347-247-5089Jeff.Boyle@arvinas.com
Media:Kirsten
Owens203-584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2023 to Apr 2024